I"Æ<h2 id="use-case-1-rheumatoid-arthritis">Use Case 1: Rheumatoid Arthritis</h2>
<p>Clinical trial to evaluate safety and efficacy of a novel biologic in early rheumatoid arthritis inadequate responders to methotrexate.</p>
<h3 id="inclusion-criteria">Inclusion Criteria:</h3>
<p><strong>Diagnosis</strong></p>
<ul>
  <li>Rheumatoid arthritis (ICD-9 714.0)</li>
  <li>Duration of disease: &lt;2 years</li>
  <li>Active disease: CRP &gt;1.2x ULN or ESR &gt;30 mm/hr (note: clinical findings generally required for enrollment, but would not be in structured data)</li>
</ul>

<p><strong>Demographics</strong></p>
<ul>
  <li>Age: Between 18 and 75 years</li>
  <li>Sex: No criteria</li>
</ul>

<p><strong>Medications</strong></p>
<ul>
  <li>Methotrexate &gt;3 months at &gt;7.5 mg/week</li>
  <li>Currently on Prednisone &lt;10 mg/day or not on prednisone</li>
  <li>No current biologic (etanercept, golimumab, adalimiumab, infliximab, certulizumab, anakinra, rituximab) or JAK inhibitor (tofacitinib)</li>
</ul>

<p><strong>Laboratory</strong></p>
<ul>
  <li>Hgb &gt;10 g/dl, ALT and AST &lt;ULN</li>
  <li>and T bili &lt;ULN, Creatinine &lt;ULN</li>
</ul>

<h3 id="exclusion-criteria">Exclusion Criteria</h3>
<ul>
  <li>Active tuberculosis</li>
  <li>Hepatitis B</li>
  <li>Hepatitis C</li>
  <li>HIV</li>
  <li>Pregnancy</li>
  <li>Enrolled in another clinical trial</li>
</ul>

<h3 id="pseudocode">Pseudocode</h3>
<div class="highlighter-rouge"><div class="highlight"><pre class="highlight"><code>Age between 18 and 75 years
AND Rheumatoid arthritis diagnosis
AND NOT [Tuberculosis, Hepatitis B, Hepatitis C, or HIV diagnosis]

AND methotrexate order
AND NOT [prednisone &gt;10 mg/day orders, tanercept, golimumab, adalimumab, infliximab, 
certolizumab, anakinra, rituximab, or tofacitinib orders] since 1 January 2014

AND NOT [Hemoglobin â‰¤10 g/dL, ALT â‰¥55 U/L, AST â‰¥48 U/L, Total bilirubin â‰¥1.0 mg/dL, 
or Creatinine â‰¥1.3 mg/dL] since 1 January 2014
</code></pre></div></div>
<h2 id="use-case-2-hepatitis-c">Use Case 2: Hepatitis C</h2>
<p>Identification of subjects with early stage fibrosis secondary to Hepatitis C infection.</p>
<h3 id="inclusion-criteria-1">Inclusion Criteria</h3>
<p><strong>Diagnosis</strong></p>
<ul>
  <li>Hepatitis C ICD9 code 070.54</li>
  <li>HCV RNA positive</li>
</ul>

<p><strong>Demographics</strong></p>
<ul>
  <li>Age: 18 to 64</li>
  <li>Sex: No criteria</li>
</ul>

<p><strong>Laboratory</strong></p>
<ul>
  <li>AST available</li>
  <li>ALT available</li>
  <li>Platelet count available</li>
</ul>

<h3 id="exclusion-criteria-1">Exclusion Criteria</h3>
<ul>
  <li>Prior treatment with interferon</li>
</ul>

<h3 id="pseudocode-1">Pseudocode</h3>
<div class="highlighter-rouge"><div class="highlight"><pre class="highlight"><code>Age between 18 and 64 years
AND Hepatitis C (ICD9 070.54) diagnosis 

AND positive Hepatitis C RNA test or Hepatitis C virus Ab or Hepatitis C virus IgG Ab
AND has Platelet measurement
AND has ALT measurement
AND has AST measurement

AND NOT [interferon order]
</code></pre></div></div>
<h2 id="use-case-3-multiple-sclerosis">Use Case 3: Multiple Sclerosis</h2>
<h3 id="inclusion-criteria-2">Inclusion Criteria:</h3>
<p><strong>Diagnosis</strong></p>
<ul>
  <li>Diagnosed with or suspected relapsing remitting multiple sclerosis optic neuritis ,transverse myelitis, cerebral or brainstem demyelinating event, neuromyelitis optica, migraine with abnormal MRI, CNS demyelinating event</li>
  <li>Duration of disease: no restriction</li>
  <li>Active disease: evidence by brain or spinal cord MRI, oligoclonal banding</li>
</ul>

<p><strong>Demographics</strong></p>
<ul>
  <li>Age: Between 18 and 65 years inclusive</li>
  <li>Sex: No criteria</li>
</ul>

<p><strong>Medications</strong></p>
<ul>
  <li>Steroids currently or anytime in the last 6 months</li>
  <li>Anti-coagulation or anti-platelet therapy (e.g. Coumadin, Pradaxa, Plavix, heparin)</li>
  <li>Use of interferon beta 1a, interferon beta 1b, glatiramer acetate, natalizumab, teroflunomide, dimethyl fumarate, fingolimod, mitoxantrone, rituximab, cyclophosphamide, IVIG) in past 6 months</li>
</ul>

<p><strong>Laboratory</strong></p>
<ul>
  <li>IgG Index any level</li>
  <li>White blood cell count</li>
  <li>Negative VDRL</li>
  <li>Myelin basic protein</li>
</ul>

<h3 id="exclusion-criteria-2">Exclusion Criteria</h3>
<ul>
  <li>History of Hepatitis B or C</li>
  <li>HIV</li>
  <li>History of lymphoma</li>
  <li>History of bone marrow transplant</li>
</ul>

<p>â€ƒ</p>
<h2 id="use-case-4-biliary-atresia">Use Case 4: Biliary atresia</h2>
<p>Rare pediatric disease use case (contributed by Ronald J. Sokol, Colorado Clinical and Translational Sciences Institute)</p>

<p>Proposed Clinical Trial: Clinical trial of new anti-fibrosis medication for children with biliary atresia who have undergone hepatic portoenterostomy and have evidence of portal hypertension but have not yet had liver transplant.</p>

<h3 id="inclusion-criteria-3">Inclusion criteria</h3>
<p><strong>Diagnosis</strong></p>
<ul>
  <li>Diagnosis of biliary atresia (ICD-9-CM 751.61)</li>
  <li>Status post Kasai hepatic portoenterostomy (ICD-9-CM 51.37 or CPT code 47701, 47765, or 47785)</li>
  <li>Presence of portal hypertension (572.3), or as defined by either platelet count &lt; 100,000 or WBC &lt; 4,000 or presence of esophageal varices (ICD-9 CM 456.0, 456.1, 456.20, 456.21)</li>
</ul>

<p><strong>Demographics</strong></p>
<ul>
  <li>Age: 2 years through 18 years</li>
  <li>Gender: No critera</li>
  <li>Race/Ethnicity: Any race or ethnic group</li>
</ul>

<h3 id="exclusion-criteria-3">Exclusion criteria</h3>
<ul>
  <li>Having undergone a liver transplantation (CPT â€“ 47135, 47136)</li>
  <li>Serum creatinine &gt; 1.5 mg/dl</li>
  <li>Asthma (ICD-9-CM 493.0, 493.1, 493.2, 493.8, 493.9)</li>
</ul>

:ET